Clinical trials: Semaglutide
Obesity, Weight Loss
Efficacy of Oral Semaglutide in Overweight or Obesity
All the eligible participants after screening will be randomized into two groups (Group 1 and 2) by block randomization (block size of 4 and 6) using computer generated random number.
- Trial name
- OSO (NCT05442450)
- Testing
- oral semaglutide
- Where
- India
- Volunteers
- 116 people
- Sponsor
- Asian Institute of Gastroenterology, India
Cannabis Use Disorder, Cue-reactivity
Semaglutide for the Treatment of Cannabis Use Disorder
The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1.
- Trial name
- S-CUD (NCT07879612)
- Testing
- semaglutide
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes.
- Trial name
- NCT05813912
- Testing
- Insulin Icodec, Semaglutide
- Where
- 39 sites in Czechia, Malaysia and 3 more
- Volunteers
- 148 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Overweight, Obesity
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine.
- Trial name
- STEP 5 (NCT03693430)
- Testing
- Semaglutide
- Where
- 41 sites in United States, Canada and 3 more
- Volunteers
- 304 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04601753)
- Testing
- Oral Semaglutide
- Where
- Sweden
- Volunteers
- 194 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.
- Trial name
- FLOW (NCT03819153)
- Testing
- Semaglutide
- Where
- 413 sites in United States, Argentina and 26 more
- Volunteers
- 3,533 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH)
Combined Active Treatment in Type 2 Diabetes With NASH
The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the…
- Conditions
- Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- COMBAT_T2_NASH (NCT04639414)
- Testing
- Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector
- Where
- 26 sites in Austria, Germany
- Volunteers
- 192 people
- Sponsor
- German Diabetes Center
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal…
- Trial name
- SUSTAIN™ 5 (NCT02305381)
- Testing
- semaglutide
- Where
- 99 sites in United States, Germany and 4 more
- Volunteers
- 397 people
- Sponsor
- Novo Nordisk A/S
Diabetes (DM), Type 2 Diabetes
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus).
- Conditions
- Diabetes (DM), Type 2 Diabetes, Obesity (Disorder)
- Trial name
- SEMA-CKM (NCT07424430)
- Testing
- Semaglutide (SEMA)
- Where
- Canada
- Volunteers
- 3,392 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Obesity, Interstitial Lung Disease
Feasibility of Semaglutide in Advanced Lung Disease
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: 1.
- Conditions
- Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary
- Trial name
- NCT05746039
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Obesity; Drug
The Effect of Weekly Semaglutide Treatment on Energy Expenditure
This study will test the effects of weekly injections of the glucagon like peptide-1 (GLP-1) agonist semaglutide on energy expenditure and metabolic parameters in a 24 week double-blind, placebo-controlled dose escalation…
- Trial name
- NCT06390501
- Testing
- Semaglutide
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested.
- Trial name
- NCT04109508
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Early Alzheimer's Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study…
- Trial name
- EVOKE (NCT04777396)
- Testing
- Semagludtide
- Where
- 447 sites in United States, Argentina and 35 more
- Volunteers
- 1,840 people
- Sponsor
- Novo Nordisk A/S
Kidney Transplant Recipient
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
- Trial name
- SPOT-DM (NCT06913023)
- Testing
- Semaglutide 0.25 mg, Semaglutide 0.5 mg, Semaglutide 1.0 mg
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- University Health Network, Toronto
Obesity
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide.
- Trial name
- NCT06131437
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 46 sites in United States
- Volunteers
- 809 people
- Sponsor
- Novo Nordisk A/S
Prediabetes / Type 2 Diabetes
A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes.
- Trial name
- NCT07195994
- Testing
- AMPK Charge+®, AMPK Charge+® with semaglutide
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- QuickSilver Scientific
Overweight and Obesity
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight.
- Trial name
- OASIS 2 (NCT05132088)
- Testing
- semaglutide 50 mg
- Where
- 15 sites in Japan, South Korea
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose…
- Trial name
- NCT06260722
- Testing
- Retatrutide, Semaglutide
- Where
- 77 sites in United States, Argentina and 3 more
- Volunteers
- 1,250 people
- Sponsor
- Eli Lilly and Company